The Efficacy and Safety of Intravenous Tranexamic Acid in Patients with Posterior Operation of Multilevel Thoracic Spine Stenosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054221

Enrollment

Unknown

Registered

2021-12-11

Start date

2018-07-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Spine Stenosis

Interventions

TXA group:Intravenous TXA (Tranexamic Acid)

Control group:Placebo

Eligibility

Sex/Gender

All

Age

25 Years to 78 Years

Inclusion criteria

Inclusion criteria: 1. CT/MRI confirmed the TSS involved at least three segments (four vertebrae); 2. Conservative treatment was ineffective and agreement of surgical treatment was obtained from the patient; 3. American Society of Anesthesiologists physical status class I, II, or III.

Exclusion criteria

Exclusion criteria: 1. Patients combined with a coagulation or hemoglobin (Hb) disorder; 2. Patients with hypo-hemoglobin (male < 120 g/L, female < 110 g/L); 3. Patients using anticoagulant or antiplatelet drugs two weeks before randomization; 4. Patients with renal insufficiency, history of thromboembolic event or significant cardiovascular disease; 5. Allergy to TXA.

Design outcomes

Primary

Measure	Time frame
Hematologica results;Complications;	—

Countries

China

Contacts

Public ContactTan Lei

Peking University International Hospital

tl6192557@126.com+86 18618266252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026